

From: Allison N Mangiaracino <Allison.N.Mangiaracino@kp.org>
Sent: Monday, October 18, 2021 5:49 PM
To: Senkewicz, MaryBeth E. (DCHBX) <marybeth.senkewicz@dc.gov>
Subject: RE: VBID Proposals Standard Plans

Hi Mary Beth,

Thank you for the opportunity to review. We have the following comments in response to the two options presented to the workgroup:

- We agree it makes sense to limit the \$0 cost share to PCP visits and nutritional counseling. The plan design should specify that the \$0 cost share applies to services with a primary diagnosis of type 2 diabetes.
- In response to Dania's comment on page 2, we suggest "preferred medications in the diabetic agents drug class as defined by the carrier." Note that this language does not specify a drug tier.
- We do not object to specifying the tests and quantity limits for lab visits with a \$0 cost share.
- These comments are contingent on Oliver Wyman's mental health parity analysis and DCHBX's legal review of nondiscrimination requirements. We request that these analyses be presented to the workgroup prior to finalizing the PY 2023 Standard Plan Designs.

Thank you,

Allison Mangiaracino (she/her)

Regulatory Consultant, Exchange Operations

Kaiser Permanente

allison.n.mangiaracino@kp.org

(916) 944-5941 (mobile)

